Functional proteomic profiling of AML predicts response and survival

Blood

Volumn 113, Issue 1, 2009, Pages 154-164

  Kornblau, Steven M ^a   Tibes, Raoul ^b   Qiu, Yi Hua ^a   Chen, Wenjing ^a   Kantarjian, Hagop M ^c   Andreeff, Michael ^a   Coombes, Kevin R ^d   Mills, Gordon B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c Departments of Leukemia

^d UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; PHOSPHOPROTEIN; ANTIBODY; PLASMA PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; BLOOD SAMPLING; BONE MARROW; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CELL CYCLE; CLINICAL FEATURE; CORRELATION ANALYSIS; CYTOGENETICS; FEMALE; HUMAN; HUMAN TISSUE; LEUKEMIA CELL; MALE; PATHOPHYSIOLOGY; PREDICTIVE VALIDITY; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ADOLESCENT; ARTICLE; CELL STRAIN HL 60; HELA CELL; LEUKEMIA CELL LINE; METABOLISM; MIDDLE AGED; MORTALITY; RECURRENT DISEASE; REMISSION; SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; BLOOD PROTEINS; BONE MARROW; FEMALE; HELA CELLS; HL-60 CELLS; HUMANS; JURKAT CELLS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROTEIN ARRAY ANALYSIS; PROTEOMICS; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 59449102553     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-10-119438     Document Type: Review

References (45)

1. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2007;109:431-448.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
3. Fresno Vara JA, Casado E, de Castro J, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30:193-204.
4. Van Etten RA. Aberrant cytokine signaling in leukemia. Oncogene. 2007;26:6738-6749.
5. Kornblau SM, Xu H-J, Zhang W, et al. Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood. 1994;84:256-261.
6. Kornblau SM, Vu HT, Ruvolo P, et al. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res. 2000;6:1401-1409.
7. Kornblau SM,Womble M, Jackson CE, et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood. 2006;108:2358-2365.
8. Kreuter M,Woelke K, Bieker R, et al. Correlation of neuropilin-1 overexpression to survival in acute myeloid leukemia. Leukemia. 2006;20:1950-1954.
9. Tanner SM, Austin JL, Leone G, et al. BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc Natl Acad Sci U S A. 2001;98:13901-13906.
10. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326-4335.
11. Bullinger L, Dohner K, Bair E, et al. Use of geneexpression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med. 2004;350:1605-1616.
12. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350:1617-1628.
13. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 2005;8:393-406.
14. Tian Q, Stepaniants SB, Mao M, et al. Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol Cell Proteomics. 2004;3:960-969.
15. Nishizuka S, Charboneau L, Young L, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A. 2003;100: 14229-14234.
16. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326-4335.
17. Cheng KW, Lu Y, Mills GB. Assay of Rab25 function in ovarian and breast cancers. Methods Enzymol. 2005;403:202-215.
18. Tibes R, Qiu YH, Lu Y, et al. Reverse phase protein array (RPPA): validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoetic stem cells (HSC). Mol Cancer Ther. 2006;5:2512-2521.
19. Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of prosurvival pathways at the cancer invasion front. Oncogene. 2001;20:1981-1989.
20. Sheehan K, Calvert VS, Kay E, et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics. 2005;4:346-355.
21. Grubb RL, Calvert VS, Wulkuhle JD, et al. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics. 2003;3: 2142-2146.
22. Hunyady B, Krempels K, Harta G, Mezey E. Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining. J Histochem Cytochem. 1996;44:1353-1362.
23. Charboneau L, Scott H, Chen T, et al. Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic. 2002;1:305-315.
24. Tabus I, Hategan A, Mircean C, et al. Nonlinear modeling of protein expression in protein arrays. IEEE Trans Signal Process. 2006;54:2394-2407.
25. Kerr MK, Churchill G. Bootstrapping cluster analysis: assessing the reliability of conclusions from microarray experiments. Proc Natl Acad Sci U S A. 2001;98:8961-8965.
26. Tibshirani R, Walther G, Hastie, T. Estimating the number of clusters in a data set via the gap statistic. J R Stat Soc Series. 2001;63:411-423.
27. Kornblau SM, Womble M, Cade JS, Lemker EM, Qiu YH. Comparative analysis of the effects of sample source and test methodology on the assessment of protein expression in acute myelogenous leukemia. Leukemia. 2005;19:1550-1557.
28. Schiffer CA, Lee E, Tomiyasu T, Wiernik P, Testa J. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood. 1989;73:263-270.
29. Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res. 2003;9:2140-2150.
30. Hayakawa F, Towatari M, Kiyoi H, et al. Tandemduplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19:624-631.
31. Choudhary C, Schwable J, Brandts C, et al. AMLassociated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood. 2005;106:265-273.
32. Gelman A, Carlin JB, Stern HS, Rubin DR. Bayesian Data Analysis (2nd ed). Boca Raton, FL: Chapman & Hall/CRC; 2004.
33. Schoch C, Dicker F, Herholz H, et al. Mutations of the Tp53 gene occur in 13.4% of acute myeloid leukemia and are strongly associated with a complex aberrant karyotype [abstract]. Blood. 2006; 108.
34. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A. 2006;103:1888-1893.
35. Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol. 2000; 111:196-203.
36. Fenaux P, Preudhomme C, Quiquandon I, et al. Mutations of the p53 gene in acute myeloid leukaemia. Br J Haematol. 1992;80:178-183.
37. Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 1994;84:3148-3157.
38. Kornblau SM, Barnett J, Qiu YH, et al. p53 protein expression levels are prognostic in AML and predict for mutational status [abstract]. Abstracts of the American Society of Hematology 40th Annual Meeting. December 8-11, 2007, Altanta, GA.
39. Kaufmann SH, Karp JE, Svingen PA, et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood. 1998;91:991-1000.
40. Dias S, Hattori K, Heissig B, et al. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce longterm remission of xenotransplanted human leukemias. Proc Natl Acad Sci U S A. 2001;98:10857-10862.
41. Schuch G, Machluf M, Bartsch G Jr, et al. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin- 1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood. 2002; 100:4622-4628.
42. Hajduch E, Litherland GJ, Hundal HS. Protein kinase B (PKB/Akt): a key regulator of glucose transport? FEBS Lett. 2001;492:199-203.
43. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A. 1999;96: 4240-4245.
44. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A. 1998;95:15587-15591.
45. Kornblau SM, Qiu YH, Palla SL, et al. Patterns and prognostic impact of PI3K-AKT pathway activation, regulation and downstream activity in AML using reverse phase proteins arrays (RPPA) [abstract]. Abstracts of the American Society of Hematology 40th Annual Meeting. December 8-11, 2007, Atlanta, GA.